rufinamide) for the adjunctive
treatment of seizures associated with Lennox-Gastaut Syndrome in patients >4 years.
This is an analysis of long-term efficacy and tolerability of adjunctive
perampanel from the blinded and open-label extension phases of Study 235, a randomized, double-blind, placebo-controlled Phase II study of adjunctive
perampanel in adolescent patients with inadequately controlled partial-onset seizures.
The overall result was that regardless of which mood stabilizer was prescribed along with adjunctive
personalized treatment, the co-primary outcomes of the benefits and harms ratio from treatment effects over time (the CGI efficacy index), and the number of necessary clinical adjustments (changes in medication excluding titrations according to scale), were virtually parallel: For each primary outcome, the P value for the estimated change in baseline was less than .
use of a subgingival controlled-release chlorhexidine chip reduces probing depth and improves attachment level compared with scaling and root planing alone.
The results are a bit equivocal and my impression is that they may require some type of adjunctive
Two double-blind studies involved 223 patients with SSRI-resistant MDD and found that 15mg per day of adjunctive
L-methylfolate can be a useful treatment strategy for SSRI partial and non-responders with MDD, while 7.
This is an important addition to the well-known value of ESL as adjunctive
rufinamide) as an adjunctive
treatment of seizures associated with Lennox-Gastaut Syndrome (LGS) in pediatric patients from one to four years of age.
The FDA's Neurological Devices Advisory Panel voted 7-5 to recommend approval, with conditions, of an implantable device that delivers electrical stimulation to the brain as an adjunctive
treatment for adults with refractory seizures.
Food and Drug Administration (FDA) approved BANZELTM (rufinamide) for the adjunctive
treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in children four and older and adults.
In this class of drugs, only aripiprazole (Ability) has a Food and Drug Administration indication for this type of depression--as adjunctive
therapy in treatment-resistant depression--though manufacturers of some of the others are pursuing approvals for depression.
75, is now applicable to the adjunctive
treatment, namely preventing relapses, of premenopausal breast cancer.